ES2763432T3 - Composiciones y métodos para la administración de ácidos nucleicos a base de nanopolímeros - Google Patents

Composiciones y métodos para la administración de ácidos nucleicos a base de nanopolímeros Download PDF

Info

Publication number
ES2763432T3
ES2763432T3 ES11838933T ES11838933T ES2763432T3 ES 2763432 T3 ES2763432 T3 ES 2763432T3 ES 11838933 T ES11838933 T ES 11838933T ES 11838933 T ES11838933 T ES 11838933T ES 2763432 T3 ES2763432 T3 ES 2763432T3
Authority
ES
Spain
Prior art keywords
nucleic acid
poly
acetylglucosamine
nanoparticle composition
glcnac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11838933T
Other languages
English (en)
Spanish (es)
Inventor
John Vournakis
Marina Demcheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Application granted granted Critical
Publication of ES2763432T3 publication Critical patent/ES2763432T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES11838933T 2010-11-06 2011-11-07 Composiciones y métodos para la administración de ácidos nucleicos a base de nanopolímeros Active ES2763432T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US41135810P 2010-11-08 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Publications (1)

Publication Number Publication Date
ES2763432T3 true ES2763432T3 (es) 2020-05-28

Family

ID=46025153

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11838933T Active ES2763432T3 (es) 2010-11-06 2011-11-07 Composiciones y métodos para la administración de ácidos nucleicos a base de nanopolímeros

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN103282024A (enExample)
AU (3) AU2013203247A1 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918452T3 (es) 2007-02-19 2022-07-15 Marine Polymer Tech Inc Composiciones hemostáticas y regímenes terapéuticos
NZ703163A (en) 2010-04-15 2016-06-24 Marinepolymer Tech Inc Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
CN103282024A (zh) * 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法
EP2696680B1 (en) 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US20060105049A1 (en) * 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
WO2008094659A2 (en) * 2007-01-31 2008-08-07 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
CN103282024A (zh) * 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法

Also Published As

Publication number Publication date
MX358050B (es) 2018-08-03
CN103282024A (zh) 2013-09-04
IL226170B (en) 2018-11-29
US20130287853A1 (en) 2013-10-31
AU2013203247A1 (en) 2013-05-09
US20170128382A1 (en) 2017-05-11
EP2635261A2 (en) 2013-09-11
CA2816999A1 (en) 2012-05-10
WO2012061803A3 (en) 2012-08-16
AU2016201640A1 (en) 2016-04-07
AU2011323078A1 (en) 2013-05-02
JP2014500250A (ja) 2014-01-09
JP6029591B2 (ja) 2016-11-24
WO2012061803A2 (en) 2012-05-10
CN108743562A (zh) 2018-11-06
JP2016164181A (ja) 2016-09-08
MX2013005016A (es) 2014-03-12
EP2635261A4 (en) 2014-09-17
US20230157971A1 (en) 2023-05-25
AU2011323078B2 (en) 2016-04-14
EP2635261B1 (en) 2019-10-23
IL226170A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US20230157971A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
US20230293608A1 (en) Oncolytic Vaccinia Virus
ES2467678T3 (es) Modificación del ARN, que produce unas estabilidad de transcripción y eficiencia de traducción aumentadas
ES2826203T3 (es) Suministro pulmonar de ARN mensajero
ES2702466T3 (es) Procedimiento para aumentar la expresión de proteínas codificadas por ARN
ES2946969T3 (es) Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
CN101203245B (zh) Rna最佳注射配方
Su et al. Nonviral gene therapy targeting cardiovascular system
Běláková et al. DNA vaccines: are they still just a powerful tool for the future?
CN102740894A (zh) 用于治疗缺血组织的sdf-1递送
JP2018537521A (ja) 広域インフルエンザウイルスワクチン
JPWO2007132873A1 (ja) 核酸、オリゴ核酸、又はその誘導体導入用の凍結乾燥体
Firouzamandi et al. Preparation, characterization, and in ovo vaccination of dextran-spermine nanoparticle DNA vaccine coexpressing the fusion and hemagglutinin genes against Newcastle disease
WO2023172547A1 (en) Nucleic acid-lipid nanoparticle and method using the same
CN119866375A (zh) 非免疫原性环状非病毒dna载体
Shi et al. Improving DNA vaccination performance through a new microbubble design and an optimized sonoporation protocol
Sun et al. Distribution characteristics of DNA vaccine encoded with glycoprotein C from Anatid herpesvirus 1 with chitosan and liposome as deliver carrier in ducks
CN121628927A (zh) 一种狂犬病毒G蛋白mRNA疫苗冻干制剂的制备及应用
Cheng et al. N‐Acetylcysteine–Mediated Surface Remodeling of Inhaled mRNA Lipid Nanoparticles Enables Coordinated Mucosal and Systemic Antitumor Immunity
US20220193229A1 (en) Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport
RU2834627C1 (ru) ДНК-последовательности, предназначенные для вакцинации человека и животных от развития заболевания, вызванного штаммами Brucella
Wang Control and Optimization of Immune Responses Induced by Nucleic Acid Vaccines
Brinkman Combining biomaterials and immunotherapeutic mRNA to combat cancer
Saber et al. Assessment of in vitro and in vivo transfection efficiency of the biodegradable polymer chitosan in the inner ear
You et al. Distribution and expression of recombinant plasmid encoding chicken interleukin-2